Seeking Alpha

Sarepta (SRPT +2.4%) CEO Chris Garabedian told the JPM healthcare conference yesterday...

Sarepta (SRPT +2.4%) CEO Chris Garabedian told the JPM healthcare conference yesterday (transcript) that his company's cash balance at the end of Q4 was $187M. Sarepta plans to meet the FDA in Q1 over its Eteplirsen drug for muscular dystrophy for end of Phase II discussions. If the talks are "favorable," Sarepta will look to file for an accelerated approval for the drug, which Garabedian reckons has a market of $600M-$1B in the U.S.
From other sites
Comments (1)
  • bil4Bill
    , contributor
    Comments (21) | Send Message
     
    cheap stock.

     

    enormous potenyial!
    10 Jan 2013, 04:32 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs